Everolimus

Advance Directives, Steroid therapy, Carcinoid Tumor + 11 more
Treatment
22 FDA approvals
0 Active Studies for Everolimus

What is Everolimus

EverolimusThe Generic name of this drug
Treatment SummaryEverolimus is a drug that works like Rapamycin, an immunosuppressant used to help prevent organ transplant rejection. It stops the mTORC1 protein from working, but does not affect the mTORC2 protein.
Afinitoris the brand name
image of different drug pills on a surface
Everolimus Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Afinitor
Everolimus
2009
59

Approved as Treatment by the FDA

Everolimus, also known as Afinitor, is approved by the FDA for 22 uses including Lung and Tuberous Sclerosis .
Lung
Tuberous Sclerosis
Neuroendocrine Tumors
pancreatic origin Progressive Neuroendocrine Tumors
Tuberous Sclerosis
Subependymal giant cell astrocytoma, tuberous sclerosis complex
metastatic gastrointestinal origin Progressive Neuroendocrine Tumors
locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors
locally advanced lung origin Progressive Neuroendocrine Tumors
unresectable gastrointestinal origin Progressive Neuroendocrine Tumors
metastatic lung origin Progressive Neuroendocrine Tumors
unresectable lung origin Progressive Neuroendocrine Tumors
Renal angiomyolipoma, tuberous sclerosis complex
Liver Transplant Rejection
Used to treat Liver Transplant Rejection in combination with Tacrolimus
Kidney Transplant Rejection
Used to treat Kidney Transplant Rejection in combination with Basiliximab
Advance Directives
Used to treat refractory, advanced Breast cancer in combination with Exemestane
refractory Advanced Renal Cell Carcinoma
Neuroendocrine Tumors
Neoplasm Metastasis
Neuroendocrine Tumors
Steroid therapy
Used to treat Steroid therapy in combination with Tacrolimus
Neuroendocrine Tumors

Effectiveness

How Everolimus works in the bodyEverolimus is a drug that targets the mTOR protein, which helps control cell growth and division. By blocking the mTOR protein, Everolimus stops cells from dividing and growing, which can stop cancer cells from spreading. It also prevents new blood vessels from forming, which starves the cancer cells of oxygen and nutrients. Finally, it reduces the amount of glucose (sugar) that cancer cells can take in, further starving them of energy.

When to interrupt dosage

The proposed measure of Everolimus is contingent upon the marked condition, including metastatic lung origin Progressive Neuroendocrine Tumors, Heart and Advance Directives. The quantity likewise fluctuates as per the approach of delivery (e.g. Tablet or Oral) featured in the table beneath.
Condition
Dosage
Administration
Advance Directives
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Steroid therapy
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Carcinoid Tumor
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Tuberous Sclerosis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Tuberous Sclerosis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Waldenstrom Macroglobulinemia
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
refractory Advanced Renal Cell Carcinoma
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Neoplasm Metastasis
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
pancreatic origin Progressive Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Lung
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral
Neuroendocrine Tumors
2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg
, Tablet, for suspension, Oral, Tablet, for suspension - Oral, Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Everolimus.
Common Everolimus Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Everolimus.
Abetimus
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Everolimus is combined with Acteoside.
Everolimus Toxicity & Overdose RiskThe drug is toxic at 0.63 nanomolar concentrations.
image of a doctor in a lab doing drug, clinical research

Everolimus Novel Uses: Which Conditions Have a Clinical Trial Featuring Everolimus?

16 active clinical trials are currently in progress to assess the potential of Everolimus in providing advanced treatment of locally advanced lung origin Progressive Neuroendocrine Tumors, advanced Carcinoid tumor and Heart ailments.
Condition
Clinical Trials
Trial Phases
pancreatic origin Progressive Neuroendocrine Tumors
0 Actively Recruiting
Steroid therapy
0 Actively Recruiting
Carcinoid Tumor
0 Actively Recruiting
Tuberous Sclerosis
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
refractory Advanced Renal Cell Carcinoma
0 Actively Recruiting
Tuberous Sclerosis
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Neuroendocrine Tumors
0 Actively Recruiting
Waldenstrom Macroglobulinemia
0 Actively Recruiting
Neoplasm Metastasis
0 Actively Recruiting
Lung
0 Actively Recruiting

Everolimus Reviews: What are patients saying about Everolimus?

4Patient Review
12/22/2014
Everolimus for Prevention of Liver Transplant Rejection
I was using this as an anti-rejection medication for my liver transplant, and it also worked well as a chemo drug against a tumor that developed in my old liver. The only issues I had were a canker sore (which was easily treated), some swelling in one lower leg (treated with lymphodema massage), and a few skin bumps/boils. I continued to use Prograf in addition to Zortress.
2Patient Review
1/27/2012
Everolimus for Cancer Involving the Kidney Cells
On the ninth day after starting this treatment, I developed severe mouth sores.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about everolimus

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is everolimus a chemotherapy?

"Everolimus works by inhibiting the growth of cancer cells.

Everolimus is a chemotherapy drug that stops cancer cells from growing. It is a type of drug called an "mTOR kinase inhibitor.""

Answered by AI

How long can you take everolimus?

"You should take everolimus every day for as long as it keeps working or until you experience unacceptable side effects. It is a long-term treatment. In clinical trials, people took the average for 24.0 weeks (range one week to almost 200 weeks)."

Answered by AI

What is the drug everolimus used for?

"Everolimus is a medication that is used to treat late-stage cancers, noncancerous tumors, such as kidney and breast cancer, subependymal giant cell astrocytoma (SEGA, a brain tumor), renal angiomyolipoma (kidney tumor), partial-onset seizures (epilepsy) with tuberous sclerosis complex (TSC), and neuroendocrine tumors."

Answered by AI

What are the side effects of everolimus?

"The following are symptoms of something wrong: bloating or swelling of the face, arms, hands, lower legs, or feet; bloody nose; chest pain or tightness; decreased weight; difficult or labored breathing; difficulty with swallowing; sores, ulcers, or white spots on the lips, tongue, or inside the mouth; tingling of the hands or feet."

Answered by AI
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top